UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8‑K
CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report: October 3, 2018
(Date of earliest event reported)
KALVISTA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
|
|
|
|
|
|
||
|
Delaware |
|
001-36830 |
|
20-0915291 |
||
|
(State or Other Jurisdiction of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
||
|
|
|
|
||||
|
55 Cambridge Parkway Suite 901E Cambridge, MA 02142
|
||||||
|
(Address of Principal Executive Offices) (Zip Code)
|
||||||
(857) 999-0075
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8‑K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
⃞ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
⃞ Soliciting material pursuant to Rule 14a‑12 under the Exchange Act (17 CFR 240.14a‑12)
⃞ Pre‑commencement communications pursuant to Rule 14d‑2(b) under the Exchange Act (17 CFR 240.14d‑2(b))
⃞ Pre‑commencement communications pursuant to Rule 13e‑4(c) under the Exchange Act (17 CFR 240.13e‑4(c)
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 5.07.Submission of Matters to a Vote of Security Holders.
On October 3, 2018, KalVista Pharmaceuticals, Inc. (the “Company”) held its 2018 Annual Meeting of Stockholders (“Annual Meeting”) and the following proposals were adopted:
|
|
1. |
Election of two Class III directors, Albert Cha, M.D., Ph.D. and Arnold L. Oronsky, Ph.D. each to serve a three-year term, which will expire at the 2021 Annual Meeting of Stockholders or until such time as their respective successors have been duly elected and qualified: |
|
Nominees |
|
Shares For |
|
Shares Withheld |
|
|
Broker Non-Votes |
|
Albert Cha M.D., Ph.D. |
|
8,488,997 |
|
1,515,312 |
|
|
1,068,831 |
|
Arnold L. Oronsky, Ph.D. |
|
8,484,853 |
|
1,519,456 |
|
|
1,068,831 |
|
|
2. |
Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending April 30, 2019: |
|
Shares For |
|
Shares Against |
|
Shares Abstaining |
|
Broker Non-Votes |
|
10,499,551 |
|
1,927 |
|
0 |
|
0 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
KalVista Pharmaceuticals, Inc.
Date: October 4, 2018By:/s/ Benjamin L. Palleiko
Name: Benjamin L. Palleiko
Title: Chief Financial Officer